Key Findings from the INTERCEPT Study

Opinion
Video

GI medical oncologists review recent findings from the INTERCEPT study evaluating the prognostic performance of circulating tumor DNA in clinical practice.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

Idylla CDx MSI Test Earns FDA Approval in MSI-H Colorectal Cancer

Roman Fabbricatore
September 16th 2025
Article
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
September 16th 2025
Podcast
Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC

Roman Fabbricatore
September 16th 2025
Article
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
September 16th 2025
Podcast
Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.

Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC

Roman Fabbricatore
September 16th 2025
Article
Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients With Stage III CRC

Roman Fabbricatore
September 16th 2025
Article